SPDR® S&P Biotech ETF (XBI)

95.05
BATS BZX Real-Time Price
As of 1:00pm ET
 +1.75 / +1.88%
Today’s Change
74.44
Today|||52-Week Range
101.55
+11.99%
Year-to-Date

Investment Objective

The investment seeks to provide investment results that- before fees and expenses- correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index")- the fund employs a sampling strategy. It generally invests substantially all- but at least 80%- of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.

No recent news for SPDR® S&P Biotech ETF.

Performance

1 month-6.87% 3 years+9.22%
3 months-0.22% 5 years+19.69%
1 year+24.65% Since inception+15.20%
Data through 08/21/2018

Quote Details

Previous close$93.30
Open day’s range93.50 – 95.22
Net asset value (NAV)93.29 (08/20/2018)
Daily volume303,827
Average volume (3 months)4,303,994
Data as of 1:00pm ET, 08/21/2018

Peer Comparisonvs. Health ETFs

 XBICategory
Performance 5-yr return+19.69%+14.50%
Expense Gross exp ratio0.35%1.29%
Risk 5 year sharpe ratio0.720.91
Net assets$5.3B$3.3B
Average market cap$3.4B$28.1B
Average P/E--28.8
Dividend / Share--0.31%

Competitors

XLV Health Care Select Sector SPDR® Fund
FHLC Fidelity MSCI Health Care Index ETF
VHT Vanguard Health Care Index Fund ETF Shar...

Holdings

Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
HRTX Heron Therapeutics Inc1.62%
ICPT Intercept Pharmaceuticals Inc1.58%
REGN Regeneron Pharmaceuticals1.58%
SRPT Sarepta Therapeutics Inc1.57%
VRTX Vertex Pharmaceuticals Inc1.54%
ESPR Esperion Therapeutics Inc1.52%
CELG Celgene1.51%
ALXN Alexion Pharmaceuticals Inc1.48%
LGND Ligand Pharmaceuticals Inc1.47%
BMRN Biomarin Pharmaceutical Inc1.47%